{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:57:34Z","timestamp":1793901454962,"version":"4.8.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency during the open label extension (weeks 41\u2013113) of the randomized controlled CLUSTER trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>During a 72-week period, patients received open-label canakinumab 150 or 300\u2009mg, every 4 or 8\u2009weeks. The disease activity was evaluated every 8\u2009weeks using physician global assessment and counting the number of flares. Concentrations of CRP and serum amyloid A protein were measured. The safety was studied by determination and classification of observed adverse events. The safety and efficacy were analysed separately in three subgroups of patients receiving a cumulative dose of less than &amp;lt;35\u2009mg\/kg, \u226535 to &amp;lt;70\u2009mg\/kg or \u226570\u2009mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 74 patients who started the CLUSTER study, 66 entered Epoch 4 and 65 completed it. During the 72-week period, 42 (64%) patients experienced no flares, while 13 (20%) had one flare, as compared with a median of 12 flares per year reported at baseline. Low physician global assessment scores were seen at the end of the study for all groups with &amp;gt;90% reporting minimal disease activity or none at all. Median CRP concentrations were consistently equal or lower than 10\u2009mg\/l, while median serum amyloid A concentrations remained only slightly above the normal range of 10\u2009mg\/l. The study showed no new or unexpected adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Canakinumab proved effective to control disease activity and prevent flares in mevalonate kinase deficiency during the 72-week study period. No new safety concerns were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT02059291. https:\/\/clinicaltrials.gov.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab696","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T07:16:18Z","timestamp":1631690178000},"page":"2088-2094","source":"Crossref","is-referenced-by-count":16,"title":["Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial"],"prefix":"10.1093","volume":"61","author":[{"given":"Jerold","family":"Jeyaratnam","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Radboudumc Expertise Center for Immunodeficiency and Autoinflammation (REIA), Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Calvo","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Hospital Universitario y Polit\u00e9cnico La Fe, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Constantin","sequence":"additional","affiliation":[{"name":"2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[{"name":"Department of Immunology, Dmitry Rogachev National Medical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hofer","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Centre Multisite Romande d'Immuno-e Rhumatologie Pediatrique, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-1916","authenticated-orcid":false,"given":"Marco","family":"Gattorno","sequence":"additional","affiliation":[{"name":"Center for Autoinflammatory Diseases and Immunodeficiencies, IRCCS, G. Gaslini"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[{"name":"University of Genoa, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology, Hematology and Rheumatology, Universite de Paris, Institut des Maladies Genetiques (IMAGINE Institute), Reference Centre for Rheumatic, AutoImmune, and Systemic Diseases in Children (RAISE), Necker Hospital, Assistance Publique-Hopitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Vastert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Levy","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Dekker","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"de Benedetti","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Ospedale Pediatrico Bambino Ges\u00f9, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Frenkel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"2022050522170383100_keab696-B1","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(84)92505-4","article-title":"Hyperimmunoglobulinemia D and periodic fever: a new syndrome","volume":"323","author":"Meer","year":"1984","journal-title":"Lancet"},{"key":"2022050522170383100_keab696-B2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/9696","article-title":"Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group","volume":"22","author":"Drenth","year":"1999","journal-title":"Nat Genet"},{"key":"2022050522170383100_keab696-B3","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022050522170383100_keab696-B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0009-8981(85)90195-0","article-title":"Mevalonic aciduria: an inborn error of cholesterol biosynthesis?","volume":"152","author":"Berger","year":"1985","journal-title":"Clin Chim Acta"},{"key":"2022050522170383100_keab696-B5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/9691","article-title":"Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome","volume":"22","author":"Houten","year":"1999","journal-title":"Nat Genet"},{"key":"2022050522170383100_keab696-B6","first-page":"301","article-title":"Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome","volume":"87","author":"van der Hilst","year":"2008","journal-title":"Nat Medicine"},{"key":"2022050522170383100_keab696-B7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.clim.2012.09.011","article-title":"Mevalonate kinase deficiency, a metabolic autoinflammatory disease","volume":"147","author":"van der Burgh","year":"2013","journal-title":"Clin Immunol"},{"key":"2022050522170383100_keab696-B8","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1542\/peds.2010-3639","article-title":"Mevalonate kinase deficiency: a survey of 50 patients","volume":"128","author":"Bader-Meunier","year":"2011","journal-title":"Pediatrics"},{"key":"2022050522170383100_keab696-B9","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/art.39763","article-title":"The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry","volume":"68","author":"ter Haar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022050522170383100_keab696-B10","first-page":"163","article-title":"[Nosologic aspects of systemic forms of very-early-onset juvenile arthritis. Apropos of 17 cases.]","volume":"60","author":"Prieur","year":"1984","journal-title":"Sem Hop"},{"key":"2022050522170383100_keab696-B11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","article-title":"Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review","volume":"72","author":"ter Haar","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522170383100_keab696-B12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/ni.3457","article-title":"Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS","volume":"17","author":"Park","year":"2016","journal-title":"Nat Immunol"},{"key":"2022050522170383100_keab696-B13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.170684","article-title":"Efficacy of continuous interleukin 1 blockade in mevalonate kinase deficiency: a multicenter retrospective study in 13 adult patients and literature review","volume":"45","author":"Deshayes","year":"2018","journal-title":"J Rheumatol"},{"key":"2022050522170383100_keab696-B14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"2022050522170383100_keab696-B15","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","article-title":"Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial","volume":"79","author":"Ozen","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab696\/40505278\/keab696.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2088\/43562314\/keab696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2088\/43562314\/keab696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T18:28:09Z","timestamp":1651775289000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/2088\/6374511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab696","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,9,23]]}}}